Open company graph database — free web & API
Login

Kei Pharma Co., Ltd.

株式会社ケイファーマK Pharma, Inc.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (non-consolidated)
17
Related companies
13
§01

Basic information

BASIC
Head office
Tri-Seven Roppongi 6F, 7-7-7 Roppongi, Minato-ku, Tokyo 106-0032
Chief executive
Hiroaki Fukushima
Capital
100,000,000 JPY
Employees (non-consolidated)
17 people
Employees (consolidated)
Start date
2016-11-01
End date
§02

Websites

1 DOMAINS
§03

Business

2
iPS-based drug discovery businessRegenerative medicine business
§04

Related companies

13 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Keio University
Group Customer
湘南ヘルスイノベーションパーク
Group
Eisai Co., Ltd.
Customer
星薬科大学
Customer
Mizuho Bank, Ltd.
Customer
Stripe International Inc.
Customer
Tsumura Co., Ltd.
Customer
Nikon Cell Innovation Co., Ltd.
Customer
Masato Co., Ltd.
Customer
株式会社凛研究所
Customer
Alfresa Pharma Co., Ltd.
Alliance
Kitasato University Kitasato Research Institute Hospital
Alliance
Jikei University
Alliance
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

12 EVENTS

Addressing unmet medical needs such as neurodegenerative diseases and spinal cord injuries is a societal challenge, and the rapid development of effective drugs and therapies is required.Sources

Established Kei Pharma Co., Ltd. in Minato-ku, Tokyo, with the purpose of researching, developing, manufacturing, and selling pharmaceutical and regenerative medicine products.Sources

Founded Kei Pharma Co., Ltd. together with Dr. Eiichi Okano of Keio University School of Medicine and Dr. Masaya Nakamura of the Department of Orthopedic Surgery.Sources

Opened Kei Pharma Lab at Shonan Health Innovation Park (Shonan AI Park).Sources

Entered into a joint research agreement with Keio University with the aim of developing pharmaceutical and regenerative medicine products utilizing iPS cells.Sources

Entered into a joint research agreement with Keio University for clinical trials of regenerative medicine using iPS cell-derived neural progenitor cells for subacute spinal cord injury.Sources

Hiroaki Fukushima was appointed President and CEO of Kei Pharma Co., Ltd.Sources

Established the "Kei Pharma-Keio Spinal Cord Regeneration Lab" in the Comprehensive Medical Science Research Building on Keio University's Shinano-cho campus.Sources

Signed a licensing agreement with Alfressa Pharma Inc. regarding the derivation of KP2011, a candidate drug for ALS in Japan.Sources

Entered into a joint research agreement with the Kitasato Institute for clinical trials of hearing loss therapeutics.Sources

Entered into a joint research agreement with the National Hospital Organization Osaka Medical Center for clinical trials of regenerative medicine for chronic stroke, cerebral hemorrhage, and traumatic central nervous system injury.Sources

Listed shares on the Tokyo Stock Exchange Growth Market.Sources

§07

News

20 ARTICLES

Interview with the President of Keifa PharmaSources

An interview with President Koaki Fukushima was published in the market news feature of 'Kabutan' dated April 16, 2026.

CEO of Kei Pharma to Speak at CPHI JAPAN 2026Sources

Hiroaki Fukushima, President and CEO of Kei Pharma Inc., will speak at CPHI JAPAN 2026 held at Tokyo Big Sight on April 22, 2026, discussing drug discovery and regenerative medicine utilizing iPS cell technology.

Kei Pharma, Nikon Cell Innovation Sign Basic AgreementSources

Kei Pharma has signed a basic agreement with Nikon Cell Innovation regarding the manufacturing consignment of clinical trial products in the spinal cord injury regenerative medicine business, and is preparing for early practical application.

Our company's iPS drug discovery business and regenerative medicine business featured in Daily Pharmaceutical NewsSources

K Pharma Co., Ltd.'s efforts in drug discovery and regenerative medicine utilizing iPS cells, as well as future strategies, were introduced in the Daily Pharmaceutical News dated December 26, 2025.

Our iPS drug discovery and regenerative medicine business featured in the Stock NewspaperSources

On December 9, 2025, the Stock Newspaper introduced our efforts in drug discovery using iPS cells and regenerative medicine, as well as our future strategies.

Our company's iPS drug discovery business and regenerative medicine business featured in the Chemical Industry DailySources

The efforts and future strategies of Ke Pharma Co., Ltd. utilizing iPS cells for drug discovery and regenerative medicine were introduced in the Chemical Industry Daily.

Kei Pharma, Partnership and Fundraising for Spinal Cord Injury TreatmentSources

Kei Pharma Co., Ltd. was reported in Nikkei Biotechnology to have entered into a business alliance regarding the supply chain for subacute spinal cord injuries and issued bonds with stock acquisition rights.

Our company's iPS drug discovery business and regenerative medicine business featured in Chemical Industry DailySources

On October 22, 2025, Chemical Industry Daily featured Ke Pharma Co., Ltd.'s efforts in drug discovery and regenerative medicine utilizing iPS cells.

Kei Pharma's iPS-based drug discovery initiative for FTDSources

Kei Pharma's iPS-based drug discovery research for frontotemporal dementia (FTD) was featured in a DIME article. The company will continue to advance the development of treatments for neurodegenerative diseases.

Interview with CSO Director Eiichi Okano Appears on AnswersNewsSources

An interview article featuring Eiichi Okano, CSO and director of Kei Pharma Co., Ltd., was published on AnswersNews, where he discusses the company's global expansion and promotion of regenerative medicine products.

§08

Public records

GOV
National Tax Agency basic information9010401128001
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社ケイファーマ
Trade name (kana)
ケイファーマ
Name in English
Corporation type
301
Address
〒106-0032 東京都港区六本木7丁目7番7号
Postal code
1060032
Prefecture code
13
City code
103
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2016-11-08
Update date
2018-05-09
Change date
2016-11-08
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
2493140
METI gBizINFO9010401128001
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
9010401128001
Trade name
株式会社ケイファーマ
Trade name (kana)
ケイファーマ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都港区六本木7丁目7番7号
Postal code
1060032
Prefecture
東京都
Prefecture code
13
City or district
港区
City code
103
Street address
六本木7丁目7番7号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
代表取締役社長 福島 弘明
Capital
10175000
Employees
20
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-05-09
Key information
9010401128001
§09

Sources & updates

SOURCES
↑